Epizyme EBITDA | EPZM

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Epizyme

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
-233 M	-221 M	-176 M	-127 M	-135 M	-110 M	-131 M	-54.3 M	-2.42 M	79 K	-20.5 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
79 K	-233 M	-110 M

Quarterly EBITDA Epizyme

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-27.2 M	-49.6 M	-	-60.2 M	-55.6 M	-63.1 M	-62.1 M	-51.7 M	-56.2 M	-50.8 M	-57.5 M	-37.3 M	-50.3 M	-30.8 M	-24.3 M	-37.8 M	-29.7 M	-34.6 M	-37.4 M	-36.8 M	-27.6 M	-32.6 M	-35.5 M	-23.6 M	-27.6 M	-22.7 M	-22.3 M	-22 M	-25.1 M	-61.1 M	-15.1 M	-19.2 M	-12.9 M	-6.74 M	16.3 M	-9.19 M	-1.81 M	-7.3 M	-4.54 M	4.88 M	5.1 M	-5.48 M	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
16.3 M	-63.1 M	-29.5 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
AbbVie ABBV	15.8 B	$ 263.04	0.49 %	$ 465 B	USA
AbCellera Biologics ABCL	-199 M	$ 11.41	2.15 %	$ 3.41 B	Canada
Фармсинтез LIFE	-22.6 M	-	-	-	Russia
Aclaris Therapeutics ACRS	-75.9 M	$ 5.53	6.02 %	$ 678 M	USA
ADC Therapeutics SA ADCT	-121 M	$ 1.09	3.74 %	$ 139 M	Schweiz
Amryt Pharma plc AMYT	-38.6 M	-	-	$ 621 M	Britain
Evelo Biosciences EVLO	-106 M	-	-14.46 %	$ 27.9 M	USA
Allakos ALLK	-115 M	-	-	$ 28.6 M	USA
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Clovis Oncology CLVS	-44.2 M	-	-7.23 %	$ 13 M	USA
Chimerix CMRX	-96.5 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	-76 M	-	-	$ 401 M	USA
ADMA Biologics ADMA	199 M	$ 8.61	0.16 %	$ 2.05 B	USA
Eiger BioPharmaceuticals EIGR	-71.5 M	-	-9.21 %	$ 2.55 M	USA
89bio ETNB	-385 M	-	-	$ 1.55 B	USA
Freeline Therapeutics Holdings plc FRLN	-96.7 M	-	-	$ 384 M	Britain
Fusion Pharmaceuticals FUSN	-97.9 M	-	-	$ 1.41 B	Canada
Guardion Health Sciences GHSI	-4.32 M	-	-0.31 %	$ 3.64 M	USA
Genocea Biosciences GNCA	-50.5 M	-	-15.0 %	$ 3.04 M	USA
Gritstone Oncology GRTS	-132 M	-	0.42 %	$ 213 M	USA
G1 Therapeutics GTHX	-39 M	-	-	$ 370 M	USA
Harpoon Therapeutics HARP	-66 M	-	-	$ 763 M	USA
Humanigen HGEN	-68.3 M	-	-81.12 %	$ 4.28 M	USA
HOOKIPA Pharma HOOK	-48.7 M	-	-6.92 %	$ 79.4 M	USA
Intercept Pharmaceuticals ICPT	-18.3 M	-	-	$ 643 M	USA
IGM Biosciences IGMS	-199 M	-	-	$ 76.9 M	USA
IMV IMV	-10.9 M	-	-	$ 13.1 M	Canada
Intra-Cellular Therapies ITCI	-116 M	-	-	$ 13.6 B	USA
Kinnate Biopharma KNTE	-120 M	-	-	$ 123 M	USA
Chinook Therapeutics KDNY	-182 M	-	-	$ 2.6 B	USA
Kaleido Biosciences KLDO	-85.3 M	-	-3.69 %	$ 12.4 M	USA
Kronos Bio KRON	-91.2 M	-	1.49 %	$ 50.8 M	USA
Karuna Therapeutics KRTX	-493 M	-	-	$ 12.2 B	USA
Landos Biopharma LABP	-22.7 M	-	0.58 %	$ 144 M	USA
La Jolla Pharmaceutical Company LJPC	21.9 M	-	-	$ 154 M	USA
LogicBio Therapeutics LOGC	-38.4 M	-	-	$ 229 M	USA
Lumos Pharma LUMO	-36.6 M	-	-	$ 35.3 M	USA
Merrimack Pharmaceuticals MACK	-2.04 M	-	-	$ 216 M	USA
Stealth BioTherapeutics Corp MITO	-46.2 M	-	-	$ 23.9 M	USA
Mirati Therapeutics MRTX	-757 M	-	-	$ 3.3 B	USA
NexImmune NEXI	-31.9 M	-	70.13 %	$ 4.12 M	USA
9 Meters Biopharma NMTR	-42 M	-	-42.97 %	$ 1.05 M	USA
InVivo Therapeutics Holdings Corp. NVIV	-10.6 M	-	-37.48 %	$ 476 K	USA
Nymox Pharmaceutical Corporation NYMX	-4.28 M	-	-19.68 %	$ 18.4 M	Canada
ObsEva SA OBSV	-54.5 M	-	-15.52 %	$ 10.5 M	Schweiz
Oncorus ONCR	-72.9 M	-	-8.54 %	$ 3.19 M	USA
OncoSec Medical Incorporated ONCS	-36.8 M	-	31.87 %	$ 1.61 M	USA
Oncternal Therapeutics ONCT	-41.7 M	-	-24.12 %	$ 1.56 M	USA
Opiant Pharmaceuticals OPNT	5.25 M	-	-	$ 109 M	USA
Orchard Therapeutics plc ORTX	-124 M	-	1.02 %	$ 90.8 M	Britain